CytoDyn provides update on PRO 140 pivotal combination therapy trial in patients with HIV
CytoDyn announces it has enrolled 34 patients in its pivotal Phase 2b/3 trial of PRO 140 in combination with antiretroviral therapy in HIV-infected patients. Thirty-three of the enrolled patients have finished the one-week efficacy endpoint of the study. August 21, 2017